Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-29T00:01:33.100Z Has data issue: false hasContentIssue false
  • English
  • Français

Reduction of depressive symptoms among patients with inflammatory bowel disease treated with biological therapy: A cross sectional study

Published online by Cambridge University Press:  13 August 2021

J. Zinkeviciute ,
R. Strumila ,
E. Dlugauskas ,
S. Brasiskiene ,
A. Kiziela  and
S. Ambrasas
J. Zinkeviciute*
Affiliation:
Medicine Faculty, Vilnius University, Vilnius, Lithuania
R. Strumila
Affiliation:
Medicine Faculty, Vilnius University, Vilnius, Lithuania
E. Dlugauskas
Affiliation:
Institute Of Clinical Medicine, Clinic Of Psychiatry, Vilnius University, Vilnius, Lithuania
S. Brasiskiene
Affiliation:
Institute Of Clinical Medicine, Clinic Of Psychiatry, Vilnius University, Vilnius, Lithuania
A. Kiziela
Affiliation:
Institute Of Clinical Medicine, Clinic Of Psychiatry, Vilnius University, Vilnius, Lithuania
S. Ambrasas
Affiliation:
Medicine Faculty, Vilnius University, Vilnius, Lithuania
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Previous studies suggest that one of the possible depression pathophysiological pathways is autoimmune inflammation increasing inflammatory mediators’ levels and thus affecting mood.

Objectives

To compare depression and anxiety symptoms among inflammatory bowel disease patients receiving TNF-α inhibitors and those receiving treatment as usual (TAU).

Methods

Instruments: Ulcerative colitis activity index, Crohn’s disease activity index, the subscale of neurovegetative symptoms of the Beck depression inventory, Hospital anxiety and depression scale. Active ulcerative colitis or Chron‘s disease patients not using antidepressants were included in the study and divided into an experimental group (receiving TNF-α inhibitors) and control group (receiving TAU).

Results

46 patients’ data were analyzed. Between the experimental group and the control group, the disease activity index was not significantly different (Chron’s disease 3.54 ±4.20; ulcerative colitis 5.70 ±5.00; p > 0.05) as well as the mean scores of the neurovegetative depression symptoms subscale of the Beck depression inventory (2.52 experimental ±3.91 control; p > 0.05). The mean score of the hospital anxiety and depression scale were significantly different between both groups (5.22 ±8.13; p < 0.05). The mean anxiety subscale scores’ p=0,06, which shows trend for significance. The mean depressive subscale score was significantly different in the control group (1.43 ±2.65; p < 0.05).

Conclusions

Patients treated with biological therapy experienced fewer depression symptoms than patients showing similar disease activity, but receiving TAU.

Keywords

tumor necrosis factor alfa inhibitorsautoimmune depressioninflammatory bowel disease.
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S336
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.